comscoreVerzenio Reduces Recurrence Risk for Certain Early-Stage Breast Cancers

Verzenio Reduces Recurrence Risk for Certain Early-Stage Breast Cancers

Stephen Johnston, MD, PhD, explains the results of the monarchE trial, which looked at adding Verzenio (abemaciclib) to standard treatment for people diagnosed with early-stage, HR-positive, HER2-negative breast cancer with a high risk of recurrence.
Sep 25, 2020
00:00
Download
00:00

At the European Society for Medical Oncology Virtual Congress 2020, Dr. Johnston presented results from the monarchE trial. This study compared treating people diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence with either standard hormonal therapy after surgery or two years of Verzenio (chemical name: abemaciclib) in addition to standard hormonal therapy.

Listen to the podcast to hear Dr. Johnston explain:

  • the characteristics that make early-stage hormone-receptor-positive, HER2-negative breast cancer have a high risk of recurrence

  • an overview of the study and its early results

  • side effects caused by Verzenio seen in the study

  • the future of using Verzenio to treat early-stage hormone-receptor-positive, HER2-negative breast cancer with a high risk of recurrence

About the guest
 
Stephen Johnston headshot
Stephen Johnston, MD, PhD

Dr. Stephen Johnston is professor of breast cancer medicine and consultant medical oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London.

— Last updated on June 29, 2022, 2:49 PM

 
Lilly

This content made possible by Lilly Oncology.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate